Figure 5. TRIM5αrh potency against FIV maps to the v1 region of the B30.2 domain.
CRFK cells expressing the indicated wild-type and TRIM5αrh-TRIM5αhu chimeric proteins (A) were Western blotted with an antibody directed against the HA epitope tag and control anti-β-actin antibody (B). Cells were challenged with FIV-GFP (C). GFP-positive cells were counted. Similar results were obtained in three independent experiments.